Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state
Open accessThe DOI matches its Crossref record; 71 of the 72 references it cites were found in a registry or an index.
Abstract
Transcriptional reprogramming of proliferative melanoma cells into a phenotypically distinct invasive cell subpopulation is a critical event at the origin of metastatic spreading. Here we generate transcriptome, open chromatin and histone modification maps of melanoma cultures; and integrate this data with existing transcriptome and DNA methylation profiles from tumour biopsies to gain insight into the mechanisms underlying this key reprogramming event. This shows thousands of genomic regulatory regions underlying the proliferative and invasive states, identifying SOX10/MITF and AP-1/TEAD as regulators, respectively. Knockdown of TEADs shows a previously unrecognized role in the invasive gene network and establishes a causative link between these transcription factors, cell invasion and sensitivity to MAPK inhibitors. Using regulatory landscapes and in silico analysis, we show that transcriptional reprogramming underlies the distinct cellular states present in melanoma. Furthermore, it reveals an essential role for the TEADs, linking it to clinically relevant mechanisms such as invasion and resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“among the SALL4-HDAC2 targets upregulated upon SALL4 knockdown, we found integrins (ITGB1, ITGA6, ITGA4), N-cadherin (CDH2), TGFBR2, VEGFR-1, PDGFC, LOXL2, MAPK8, and many others which are associated with invasive melanoma phenotypes40–42”
From Epigenetic control of melanoma cell invasiveness by the stem cell factor SALL4 (2021) · cites this paper as [41]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“SALL4-regulated genes showed a significant enrichment and positive correlation with published invasiveness signatures40–42, while they significantly anti-correlated with their corresponding proliferation signatures40–42”
From Epigenetic control of melanoma cell invasiveness by the stem cell factor SALL4 (2021) · cites this paper as [41]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
HTSeq—a Python framework to work with high-throughput sequencing data
Anders, S., Pyl, P. T., & Huber, W. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btu638 · Cited by 21,464
Model-based Analysis of ChIP-Seq (MACS)
Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386
An integrated encyclopedia of DNA elements in the human genome
The ENCODE Project Consortium (2012) · Nature · doi:10.1038/nature11247 · Cited by 18,072
Gene Expression Omnibus: NCBI gene expression and hybridization array data repository
Edgar, R. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.1.207 · Cited by 13,288
Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R., & Salzberg, S. L. (2013) · Genome Biology · doi:10.1186/gb-2013-14-4-r36 · Cited by 12,668
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Cited by
Items 101–200 of 529
Emerging Principles in the Transcriptional Control by YAP and TAZ
Lopez-Hernandez, A., Sberna, S., & Campaner, S. (2021) · Cancers · doi:10.3390/cancers13164242 · Cited by 69
Ng, M. F., Simmons, J. L., & Boyle, G. M. (2022) · Cancers · doi:10.3390/cancers14123030 · Cited by 71
Eliades, P. J., Abraham, B. J., Ji, Z., Miller, D. M., Christensen, C. L., Kwiatkowski, N. P., Kumar, R., Njauw, C.-N. J., Taylor, M., Miao, B., et al. (2018) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.09.056 · Cited by 60
Disrupting cellular memory to overcome drug resistance
Harmange, G., Hueros, R. A. R., Schaff, D. L., Emert, B., Saint-Antoine, M., Kim, L. C., Niu, Z., Nellore, S., Fane, M. E., Alicea, G. M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41811-8 · Cited by 60
Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack
Mahmoud, F. A., Shields, B. D., Makhoul, I., Avaritt, N. L., Wong, H. K., Hutchins, L. F., Shalin, S. C., & Tackett, A. J. (2017) · Cancer Biology & Therapy · doi:10.1080/15384047.2017.1323596 · Cited by 60
Extracellular Vesicles and Epigenetic Modifications Are Hallmarks of Melanoma Progression
Mannavola, F., D’Oronzo, S., Cives, M., Stucci, L. S., Ranieri, G., Silvestris, F., & Tucci, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010052 · Cited by 57
Hartman, M. L., Sztiller-Sikorska, M., Gajos-Michniewicz, A., & Czyż, M. (2020) · Cells · doi:10.3390/cells9010142 · Cited by 57
Menon, D. R., Hammerlindl, H., Torrano, J., Schaider, H., & Fujita, M. (2020) · Theranostics · doi:10.7150/thno.42523 · Cited by 58
Malt, A. L., Benhaddou, A., Zider, A., & Flagiello, D. (2016) · Gene · doi:10.1016/j.gene.2016.07.028 · Cited by 56
Obier, N., Cauchy, P., Assi, S. A., Gilmour, J., Lie‐A‐Ling, M., Lichtinger, M., Hoogenkamp, M., Noailles, L., Cockerill, P. N., Lacaud, G., et al. (2016) · Development · doi:10.1242/dev.139857 · Cited by 63
SMAD signaling promotes melanoma metastasis independently of phenotype switching
Tuncer, E., Calçada, R. R., Zingg, D., Varum, S., Cheng, P. F., Freiberger, S. N., Deng, C., Kleiter, I., Levesque, M. P., Dummer, R., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci94295 · Cited by 61
Effern, M., Glodde, N., Braun, M., Liebing, J., Boll, H. N., Yong, M. C. R., Bawden, E., Hinze, D., Konijnenberg, D., Daoud, M., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.07.007 · Cited by 58
Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma
Frede, J., Anand, P., Sotudeh, N., Pinto, R. A., Nair, M. S., Stuart, H., Yee, A. J., Vijaykumar, T., Waldschmidt, J. M., Potdar, S. V., et al. (2021) · Nature Cell Biology · doi:10.1038/s41556-021-00766-y · Cited by 64
Leclerc, J., Garandeau, D., Pandiani, C., Gaudel, C., Bille, K., Nottet, N., Garcia, V., Colosetti, P., Pagnotta, S., Bahadoran, P., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0500-0 · Cited by 54
NFATc2 is an intrinsic regulator of melanoma dedifferentiation
Perotti, V., Baldassari, P., Molla, A., Vegetti, C., Bersani, I., Maurichi, A., Santinami, M., Anichini, A., & Mortarini, R. (2015) · Oncogene · doi:10.1038/onc.2015.355 · Cited by 52
Cancer Cell Phenotype Plasticity as a Driver of Immune Escape in Melanoma
Benboubker, V., Boivin, F., Dalle, S., & Caramel, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.873116 · Cited by 55
DNA hypermethylation is associated with invasive phenotype of malignant melanoma
Koroknai, V., Szász, I., Hernández‐Vargas, H., Fernández‐Jiménez, N., Cuenin, C., Herceg, Z., Vízkeleti, L., Ádány, R., Ecsedi, S., & Balázs, M. (2019) · Experimental Dermatology · doi:10.1111/exd.14047 · Cited by 51
Corrales, E., Levit‐Zerdoun, E., Metzger, P., Mertes, R., Lehmann, A., Münch, J., Lemke, S., Kowar, S., & Boerries, M. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00989-y · Cited by 54
A geometric approach to characterize the functional identity of single cells
Mohammadi, S., Ravindra, V., Gleich, D. F., & Grama, A. (2018) · Nature Communications · doi:10.1038/s41467-018-03933-2 · Cited by 51
Laurette, P., Coassolo, S., Davidson, G., Michel, I., Gambi, G., Yao, W., Sohier, P., Li, M., Mengus, G., Larue, L., et al. (2019) · Cell Death and Differentiation · doi:10.1038/s41418-019-0333-6 · Cited by 55
Conserved Epigenetic Regulatory Logic Infers Genes Governing Cell Identity
Shim, W. J., Sinniah, E., Xu, J., Vitrinel, B., Alexanian, M., Andreoletti, G., Shen, S., Sun, Y., Balderson, B., Boix, C. A., et al. (2020) · Cell Systems · doi:10.1016/j.cels.2020.11.001 · Cited by 51
Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy
Gallagher, S. J., Tiffen, J. C., & Hersey, P. (2015) · Cancers · doi:10.3390/cancers7040870 · Cited by 50
Wessely, A., Steeb, T., Berking, C., & Heppt, M. V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115761 · Cited by 55
Interpretation of allele-specific chromatin accessibility using cell state–aware deep learning
Atak, Z. K., Taskiran, I. I., Demeulemeester, J., Flerin, C., Mauduit, D., Minnoye, L., Hulselmans, G., Christiaens, V., Ghanem, G.-E., Wouters, J., et al. (2021) · Genome Research · doi:10.1101/gr.260851.120 · Cited by 48
“gov/geo/) under accession number GSE60666 (Verfaillie et al. 2015).”
BackgroundMethodInfluentialSelf-citationNeuropilin 1 (NRP1) is a novel tumor marker in hepatocellular carcinoma
Lin, J., Zhang, Y., Wu, J., Li, L., Chen, N., Ni, P., Song, L., & Liu, X. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.06.046 · Cited by 55
Smith, M. P., Rana, S., Ferguson, J., Rowling, E. J., Flaherty, K. T., Wargo, J. A., Marais, R., & Wellbrock, C. (2018) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12741 · Cited by 50
Herbert, K., Binet, R., Lambert, J.-P., Louphrasitthiphol, P., Kalkavan, H., Sesma-Sanz, L., Robles-Espinoza, C. D., Sarkar, S., Suer, E., Andrews, S., et al. (2019) · Genes & Development · doi:10.1101/gad.314633.118 · Cited by 45
Signaling and Immune Regulation in Melanoma Development and Responses to Therapy
Lin, W. M., & Fisher, D. E. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-052016-100208 · Cited by 52
Connecting Metabolic Rewiring With Phenotype Switching in Melanoma
Falletta, P., Goding, C. R., & Vivas, Y. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.930250 · Cited by 48
Role of extracellular matrix architecture and signaling in melanoma therapeutic resistance
Popovic, A., & Tartare‐Deckert, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.924553 · Cited by 50
Regulation of Melanoma Progression through the TCF4/miR-125b/NEDD9 Cascade
Rambow, F., Bechadergue, A., Luciani, F., Gros, G., Domingues, M. J., Bonaventure, J., Meurice, G., Marine, J., & Larue, L. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.02.803 · Cited by 45
Self-citationAn actionable axis linking NFATc2 to EZH2 controls the EMT-like program of melanoma cells
Perotti, V., Baldassari, P., Molla, A., Nicolini, G., Bersani, I., Grazia, G., Benigni, F., Maurichi, A., Santinami, M., Anichini, A., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0729-2 · Cited by 46
The metabolic milieu in melanoma: Role of immune suppression by CD73/adenosine
Passarelli, A. M., Tucci, M., Mannavola, F., Felici, C., & Silvestris, F. (2019) · Tumor Biology · doi:10.1177/1010428319837138 · Cited by 46
SOX10-MITF pathway activity in melanoma cells
Tudrej, K. B., Czepielewska, E., & Kozłowska−Wojciechowska, M. (2016) · Archives of Medical Science · doi:10.5114/aoms.2016.60655 · Cited by 50
Genetic and Genomic Pathways of Melanoma Development, Invasion and Metastasis
Motwani, J., & Eccles, M. R. (2021) · Genes · doi:10.3390/genes12101543 · Cited by 50
Targeting of the Lipid Metabolism Impairs Resistance to BRAF Kinase Inhibitor in Melanoma
Vergani, E., Beretta, G. L., Aloisi, M., Costantino, M., Corno, C., Frigerio, S., Tinelli, S., Dugo, M., Accattatis, F. M., Granata, A., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.927118 · Cited by 46
Lipid droplets are a metabolic vulnerability in melanoma
Lumaquin, D., Montal, E. D., Johns, E., Baggiolini, A., Huang, T. H., Ma, Y., LaPlante, C., Suresh, S., Studer, L., & White, R. M. (2023) · Nature Communications · doi:10.1038/s41467-023-38831-9 · Cited by 50
Gelato, K. A., Schöckel, L., Klingbeil, O., Rückert, T., Lesche, R., Toedling, J., Kalfon, E., Héroult, M., Lejeune, P., Mönning, U., et al. (2017) · Oncogene · doi:10.1038/onc.2017.325 · Cited by 44
Altered BAF occupancy and transcription factor dynamics in PBAF-deficient melanoma
Carcamo, S., Nguyen, C. B., Grossi, E., Filipescu, D., Alpsoy, A., Dhiman, A., Sun, D., Narang, S., Imig, J., Martin, T. C., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110637 · Cited by 46
The MITF regulatory network in melanoma
Chauhan, J. S., Hölzel, M., Lambert, J., Buffa, F. M., & Goding, C. R. (2022) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.13053 · Cited by 44
SOX10 requirement for melanoma tumor growth is due, in part, to immune-mediated effects
Rosenbaum, S. R., Tiago, M., Caksa, S., Capparelli, C., Purwin, T. J., Kumar, G., Glasheen, M. Q., Pomante, D., Kotas, D., Chervoneva, I., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110085 · Cited by 49
Regulation of LncRNAs in Melanoma and Their Functional Roles in the Metastatic Process
Melixetian, M. B., Pelicci, P. G., & Lanfrancone, L. (2022) · Cells · doi:10.3390/cells11030577 · Cited by 46
TFAP2 paralogs facilitate chromatin access for MITF at pigmentation and cell proliferation genes
Kenny, C., Dilshat, R., Seberg, H., Otterloo, E. V., Bonde, G., Helverson, A., Franke, C. M., Steingrímsson, E., & Cornell, R. A. (2022) · PLoS Genetics · doi:10.1371/journal.pgen.1010207 · Cited by 43
Safety Considerations in the Development of Hippo Pathway Inhibitors in Cancers
Kakiuchi-Kiyota, S., Schutten, M. M., Zhong, Y., Crawford, J. J., & Dey, A. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00156 · Cited by 42
BORIS/CTCFL promotes a switch from a proliferative towards an invasive phenotype in melanoma cells
Janssen, S. M., Moscona, R., Elchebly, M., Papadakis, A. I., Redpath, M., Wang, H., Rubin, E., van Kempen, L. C. L. T., & Spatz, A. (2020) · Cell Death Discovery · doi:10.1038/s41420-019-0235-x · Cited by 41
Emmons, M. F., Bennett, R. L., Riva, A., Gupta, K., Carvalho, L. A. D. C., Zhang, C., Macaulay, R. J. B., Dupéré-Richer, D., Fang, B., Seto, E., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43519-1 · Cited by 39
Enhancer reprogramming in tumor progression: a new route towards cancer cell plasticity
Fagnocchi, L., Poli, V., & Zippo, A. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2820-1 · Cited by 40
Najem, A., Soumoy, L., Sabbah, M., Krayem, M., Awada, A. H., Journé, F., & Ghanem, G. (2022) · Cells · doi:10.3390/cells11071157 · Cited by 40
Self-citationTargeted chemotherapy overcomes drug resistance in melanomaPreprint
Yue, J., Vendramin, R., Liu, F., Lopez, O., Valencia, M. G., Santos, H. G. D., Gaidosh, G., Beckedorff, F., Blumenthal, E., Speroni, L., et al. (2020) · Genes & Development · doi:10.1101/gad.333864.119 · Cited by 38
Self-citationAn Updated Understanding of the Role of YAP in Driving Oncogenic Responses
Morciano, G., Vezzani, B., Missiroli, S., Boncompagni, C., Pinton, P., & Giorgi, C. (2021) · Cancers · doi:10.3390/cancers13123100 · Cited by 39
He, D., Xin, T., Pang, B., Sun, J., Liu, Z., Qin, Z., Ji, X. S., Yang, F., Wei, Y. B., Wang, Z. X., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02543-7 · Cited by 39
Directed Dedifferentiation Using Partial Reprogramming Induces Invasive Phenotype in Melanoma Cells
Knappe, N., Novak, D., Weina, K., Bernhardt, M., Reith, M., Larribère, L., Hölzel, M., Tüting, T., Gebhardt, C., Umansky, V., et al. (2016) · Stem Cells · doi:10.1002/stem.2284 · Cited by 36
Bruneel, K., Verstappe, J., Vandamme, N., & Berx, G. (2020) · Cancers · doi:10.3390/cancers12082248 · Cited by 37
New Insights into the Role of Sphingolipid Metabolism in Melanoma
Carrié, L., Virazels, M., Dufau, C., Montfort, A., Levade, T., Ségui, B., & Andrieu‐Abadie, N. (2020) · Cells · doi:10.3390/cells9091967 · Cited by 37
EZH2 Inhibitor Enhances the STING Agonist‒Induced Antitumor Immunity in Melanoma
Xu, T., Dai, J., Tang, L., Yang, L., Si, L., Sheng, X., Cui, C., Chi, Z., Kong, Y., & Guo, J. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.08.437 · Cited by 39
Long, E., Yin, J., Funderburk, K. M., Xu, M., Feng, J., Kane, A., Zhang, T., Myers, T., Golden, A., Thakur, R., et al. (2022) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2022.11.006 · Cited by 43
Multi-modal molecular programs regulate melanoma cell state
Andrews, M. C., Oba, J., Wu, C., Zhu, H., Karpinets, T. V., Creasy, C. A., Forget, M., Yu, X., Song, X., Mao, X., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31510-1 · Cited by 36
Adapt, Recycle, and Move on: Proteostasis and Trafficking Mechanisms in Melanoma
Demirsoy, Ş., Martín-Acebes, M. A., Maes, H., & Agostinis, P. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00240 · Cited by 39
Epigenetic control of melanoma cell invasiveness by the stem cell factor SALL4
Diener, J., Baggiolini, A., Pernebrink, M., Dalcher, D., Lerra, L., Cheng, P. F., Varum, S., Häusel, J., Stierli, S., Treier, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25326-8 · Cited by 34
Proteomic identification of a marker signature for MAPKi resistance in melanoma
Paulitschke, V., Eichhoff, O. M., Gerner, C., Paulitschke, P., Bileck, A., Mohr, T. T., Cheng, P. F., Leitner, A., Guenova, E., Saulīte, I., et al. (2019) · The EMBO Journal · doi:10.15252/embj.201695874 · Cited by 34
NRF2 Enables EGFR Signaling in Melanoma Cells
Kreß, J. K. C., Jessen, C., Marquardt, A., Hufnagel, A., & Meierjohann, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083803 · Cited by 34
Pillai, M., & Jolly, M. K. (2021) · iScience · doi:10.1016/j.isci.2021.103111 · Cited by 36
Hölzel, M., Landsberg, J., Glodde, N., Bald, T., Rogava, M., Riesenberg, S., Becker, A. J., Jonsson, G. G., & Tüting, T. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1090 · Cited by 33
Singh, M., Cai, H., Bunse, M., Feschotte, C., & Izsvák, Z. (2020) · Viruses · doi:10.3390/v12111303 · Cited by 36
Hierarchy of TGFβ/SMAD, Hippo/YAP/TAZ, and Wnt/β-catenin signaling in melanoma phenotype switching
Lüönd, F., Pirkl, M., Hisano, M., Prestigiacomo, V., Kalathur, R. K. R., Beerenwinkel, N., & Christofori, G. (2021) · Life Science Alliance · doi:10.26508/lsa.202101010 · Cited by 37
CRISPR screens identify tumor‐promoting genes conferring melanoma cell plasticity and resistance
Gautron, A., Bachelot, L., Aubry, M., Leclerc, D., Quéméner, A. M., Corre, S., Rambow, F., Paris, A., Tardif, N., Leclair, H. M., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013466 · Cited by 36
Self-citationMechanical Force Directs Proliferation and Differentiation of Stem Cells
Hu, D., Dong, Z., Li, B., Lu, F., & Li, Y. (2022) · Tissue Engineering Part B Reviews · doi:10.1089/ten.teb.2022.0052 · Cited by 33
Melixetian, M. B., Bossi, D., Mihailovich, M., Punzi, S., Barozzi, I., Marocchi, F., Cuomo, A., Bonaldi, T., Testa, G., Marine, J., et al. (2021) · EMBO Reports · doi:10.15252/embr.202050852 · Cited by 32
Self-citationKavran, A. J., Stuart, S. A., Hayashi, K. R., Basken, J., Brandhuber, B. J., & Ahn, N. G. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2113535119 · Cited by 36
Clinical Significance of SOX10 Expression in Human Pathology
Bahmad, H. F., Thiravialingam, A., Sriganeshan, K., Gonzalez, J., Alvarez, V., Ocejo, S., Abreu, A. D. C., Avellan, R., Arzola, A., Hachem, S., et al. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45120633 · Cited by 34
Plasticity and Functional Heterogeneity of Cancer-Associated Fibroblasts
Flynn, J. M., Thadani, N., Gallagher, E. E., Azzaro, I., Bodnar, C. M., McCarty, C. P., Romano, G., Webster, M. R., & Capparelli, C. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-3037 · Cited by 39
The histone demethylase PHF8 regulates TGFβ signaling and promotes melanoma metastasis
Moubarak, R. S., de Pablos-Aragoneses, A., Ortiz-Barahona, V., Gong, Y., Gowen, M. F., Dolgalev, I., Shadaloey, S. A. A., Argibay, D., Karz, A., Itter, R. V., et al. (2022) · Science Advances · doi:10.1126/sciadv.abi7127 · Cited by 30
Larribère, L., & Utikal, J. S. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00111 · Cited by 31
Lui, J. W., Moore, S. P. G., Huang, L., Ogomori, K., Li, Y., & Lang, D. (2021) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.13013 · Cited by 33
Prouteau, A., Mottier, S., Primot, A., Cadieu, É., Bachelot, L., Botherel, N., Cabillic, F., Houël, A., Cornevin, L., Kergal, C., et al. (2022) · Cancers · doi:10.3390/cancers14020276 · Cited by 34
Mengoni, M., Braun, A. D., Gaffal, E., & Tüting, T. (2020) · International Journal of Cancer · doi:10.1002/ijc.33252 · Cited by 29
Liu, J., Rebecca, V. W., Kossenkov, A. V., Connelly, T., Liu, Q., Gutierrez, A., Xiao, M., Li, L., Zhang, G., Samarkina, A., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-1496 · Cited by 31
Analysis of long and short enhancers in melanoma cell states
Mauduit, D., Minnoye, L., Taskiran, I. I., Waegeneer, M. D., Christiaens, V., Hulselmans, G., Demeulemeester, J., Wouters, J., & Aerts, S. (2021) · eLife · doi:10.7554/elife.71735 · Cited by 43
Self-citationSubhadarshini, S., Sahoo, S., Debnath, S., Somarelli, J. A., & Jolly, M. K. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006766 · Cited by 33
Shared enhancer gene regulatory networks between wound and oncogenic programs
Floc'hlay, S., Balaji, R., Stanković, D., Christiaens, V. M., Bravo González-Blas, C., De Winter, S., Hulselmans, G. J., De Waegeneer, M., Quan, X., Koldere, D., et al. (2023) · eLife · doi:10.7554/elife.81173 · Cited by 27
Self-citationDurand, S., Tang, Y., Pommier, R. M., Benboubker, V., Grimont, M., Boivin, F., Barbollat‐Boutrand, L., Cumunel, E., Dupeuble, F., Eberhardt, A., et al. (2024) · Oncogene · doi:10.1038/s41388-024-03010-7 · Cited by 29
CREsted: modeling genomic and synthetic cell-type-specific enhancers across tissues and species
Kempynck, N., Winter, S. D., Blaauw, C. H., Konstantakos, V., Ekşi, E. C., Dieltiens, S., Abaffyová, D., Bercier, V., Taskiran, I. I., Hulselmans, G. J., et al. (2026) · Nature Methods · doi:10.1038/s41592-026-03057-2 · Cited by 31
Self-citationSiena, Á. D. D., Plaça, J. R., de Araújo, L. F., de Barros, I. I., Peronni, K. C., de Molfetta, G. A., de Biagi, C. A. O., Espreáfico, E. M., Sousa, J. F., & Silva, W. A. (2019) · Scientific Reports · doi:10.1038/s41598-019-47363-6 · Cited by 29
Cooperative behaviour and phenotype plasticity evolve during melanoma progression
Rowling, E. J., Miskolczi, Z., Nagaraju, R. T., Wilcock, D. J., Wang, P., Telfer, B. A., Li, Y., Lasheras-Otero, I., Redondo-Muñoz, M., Sharrocks, A. D., et al. (2020) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12873 · Cited by 27
Rovera, C., Berestjuk, I., Lecacheur, M., Tavernier, C., Diazzi, S., Pisano, S., Irondelle, M., Mallavialle, A., Albrengues, J., Gaggioli, C., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-0501 · Cited by 28
Escape from NK cell tumor surveillance by NGFR-induced lipid remodeling in melanoma
Lehmann, J., Caduff, N., Krzywińska, E., Stierli, S., Salas-Bastos, A., Loos, B., Levesque, M. P., Dummer, R., Stockmann, C., Münz, C., et al. (2023) · Science Advances · doi:10.1126/sciadv.adc8825 · Cited by 30
Epigenetic modulation reveals differentiation state specificity of oncogene addiction
Khaliq, M., Manikkam, M., Martínez, E. D., & Fallahi‐Sichani, M. (2021) · Nature Communications · doi:10.1038/s41467-021-21784-2 · Cited by 29
The AhR‐SRC axis as a therapeutic vulnerability in BRAFi‐resistant melanoma
Paris, A., Tardif, N., Baietti, F. M., Berra, C., Leclair, H. M., Leucci, E., Galibert, M., & Corre, S. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202215677 · Cited by 26
Nongenetic Mechanisms of Drug Resistance in Melanoma
Rebecca, V. W., & Herlyn, M. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033533 · Cited by 32
Epigenetics Regulates Antitumor Immunity in Melanoma
Chen, Y., Yi, X., Sun, N., Guo, W., & Li, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.868786 · Cited by 27
Inactivation of the Hippo tumor suppressor pathway promotes melanoma
Vittoria, M. A., Kingston, N. M., Kotýnková, K., Xia, E., Hong, R., Huang, L., McDonald, S., Tilston-Lünel, A., Darp, R., Campbell, J. D., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31399-w · Cited by 31
Unsupervised Gene Network Inference with Decision Trees and Random Forests
Huynh‐Thu, V. A., & Geurts, P. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8882-2_8 · Cited by 29
Sestito, R., Tocci, P., Román, C., Castro, V. D., & Bagnato, A. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02317-1 · Cited by 28
Howard, A., Bojko, J., Flynn, B. P., Bowen, S., Jungwirth, U., & Walko, G. (2022) · Experimental Dermatology · doi:10.1111/exd.14655 · Cited by 29
Pillai, M., Chen, Z., Jolly, M. K., & Li, C. (2022) · iScience · doi:10.1016/j.isci.2022.105499 · Cited by 25
Tsai, C.-R., Anderson, A. E., Burra, S., Jo, J.-Y., & Galko, M. J. (2017) · Developmental Biology · doi:10.1016/j.ydbio.2017.05.006 · Cited by 25
Program, N. C. S., Fufa, T., Baxter, L. L., Wedel, J. C., Gildea, D. E., Loftus, S. K., & Pavan, W. J. (2019) · Epigenetics & Chromatin · doi:10.1186/s13072-019-0297-2 · Cited by 40
Epigenetic regulation during melanocyte development and homeostasis
Dilshat, R., Vu, H. N., & Steingrímsson, E. (2021) · Experimental Dermatology · doi:10.1111/exd.14391 · Cited by 23
Epigenetic Mechanisms Underlying Melanoma Resistance to Immune and Targeted Therapies
Rubanov, A., Berico, P., & Hernando, E. (2022) · Cancers · doi:10.3390/cancers14235858 · Cited by 25
ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
Eichhoff, O. M., Stoffel, C. I., Käsler, J., Briker, L., Turko, P., Karsai, G., Zila, N., Paulitschke, V., Cheng, P. F., Leitner, A., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-1826 · Cited by 28
Metadata
- Authors
- Verfaillie, A., Imrichova, H., Atak, Z. K., Dewaele, M., Rambow, F., Hulselmans, G., Christiaens, V., Svetlichnyy, D., Luciani, F., Van den Mooter, L., Claerhout, S., Fiers, M., Journe, F., Ghanem, G.-E., Herrmann, C., Halder, G., Marine, J.-C., & Aerts, S.
- Affiliations
- KU Leuven (BE)
- VIB-KU Leuven Center for Cancer Biology (BE)
- Université Libre de Bruxelles (BE)
- German Cancer Research Center (DE)
- Corresponding author
- Aerts, Stein
- ORCID
- Venue
- Nature Communications
- Published
- 2015-04-09
- Volume
- 6
- Issue
- 1
- Pages
- 6683-6683
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC4403341
- OpenAlex
- W2018433132
- Cited by
- 489
- References
- 72
- Citations by year
- 2026: 27 · 2025: 32 · 2024: 59 · 2023: 56 · 2022: 59 · 2021: 50 · 2020: 56 · 2019: 41 · 2018: 33 · 2017: 39 · 2016: 24 · 2015: 11
- FWCI
- 15.48
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Lirias (KU Leuven) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
- Funders
- Fonds Wetenschappelijk Onderzoek
- KU Leuven
- Kom op tegen Kanker
- Fondation contre le Cancer
- Stand Up To Cancer
- Bijzonder Onderzoeksfonds UGent
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- melanoma, cell invasion, transcriptional reprogramming, TEAD transcription factors, SOX10, MITF, AP-1, MAPK inhibitors, MAPK inhibitor resistance, chromatin accessibility, histone modifications, DNA methylation, metastasis
- MeSH terms
- TEA Domain Transcription Factors, Antineoplastic Agents, Cell Transformation, Neoplastic, Chromatin, DNA-Binding Proteins, Histones, Humans, Melanoma, Neoplasm Invasiveness, Nuclear Proteins, Transcription Factors, Transcription, Genetic, Signal Transduction, Gene Expression Regulation, Neoplastic, Transcription Factor AP-1, DNA Methylation, Protein Isoforms, RNA, Small Interfering, Cell Line, Tumor, Protein Kinase Inhibitors, Microphthalmia-Associated Transcription Factor, Gene Regulatory Networks, SOXE Transcription Factors, Transcriptome, Cellular Reprogramming
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.